Related Experiment Videos
Lack of c-erbB-2 oncoprotein expression in male breast carcinoma
Abstract:
A series of 21 male breast carcinomas were immunostained using NCL-CB11, an antibody directed against the internal domain of the c-erbB-2 transmembrane oncoprotein. In contrast to female breast cancer, where up to 35% of cases show positivity, all of these cases were negative. This suggests that no prognostic information regarding patient survival can be made in these patients and that male breast carcinomas may be under different growth control mechanisms from female breast carcinomas.
Insights
Male breast carcinomas showed no c-erbB-2 oncoprotein expression, unlike female breast cancer. This indicates different growth mechanisms and no prognostic value for this marker in males.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- c-erbB-2 oncoprotein is a transmembrane protein implicated in various cancers.
- Expression of c-erbB-2 is a significant prognostic factor in female breast cancer.
- Limited data exists on c-erbB-2 expression in male breast carcinomas.
Purpose of the Study:
- To investigate the expression of c-erbB-2 in male breast carcinomas.
- To determine if c-erbB-2 expression has prognostic value in male breast cancer.
- To compare c-erbB-2 expression patterns between male and female breast carcinomas.
Main Methods:
- Immunohistochemical staining of 21 male breast carcinoma tissue samples.
- Utilized the NCL-CB11 antibody, targeting the internal domain of c-erbB-2.
- Compared results with known c-erbB-2 expression rates in female breast cancer.
Main Results:
- All 21 male breast carcinoma cases tested negative for c-erbB-2 expression.
- In contrast, up to 35% of female breast cancer cases exhibit c-erbB-2 positivity.
- Absence of c-erbB-2 suggests it may not be a relevant biomarker for male breast cancer prognosis.
Conclusions:
- c-erbB-2 oncoprotein is not expressed in the studied male breast carcinomas.
- The lack of expression implies no prognostic information can be derived from c-erbB-2 in male breast cancer.
- Male breast carcinomas may be regulated by distinct growth control mechanisms compared to their female counterparts.